Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancers × Pemetrexed × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 535 Lung Neoplasms 168 Neoplasms 62 Mesothelioma, Malignant 43 Neoplasm Metastasis 39 Adenocarcinoma of Lung 36 Mesothelioma 35 Colorectal Neoplasms 26 Breast Neoplasms 21 Meningeal Carcinomatosis 20 Parkinson Disease 4, Autosomal Dominant Lewy Body 19 Carcinoma 19 Head and Neck Neoplasms 17 Brain Neoplasms 16 Adenocarcinoma 15 Ovarian Neoplasms 14 Small Cell Lung Carcinoma 12 Squamous Cell Carcinoma of Head and Neck 11 Recurrence 11 NSCLC 11 Pancreatic Neoplasms 10 Uterine Cervical Neoplasms 9 Neoplasms by Site 9 Melanoma 8 Lung Diseases 8 Carcinoma, Transitional Cell 8 Stomach Neoplasms 7 Endometrial Neoplasms 7 Carcinoma, Bronchogenic 7 Adenocarcinoma, Bronchiolo-Alveolar 7

Interventions

Surveys and Questionnaires 5 pazopanib 3 Erlotinib Hydrochloride 3 Cetuximab 3 Vorinostat 2 Oxaliplatin 2 Bevacizumab 2 Azacitidine 2 satraplatin 1 ridaforolimus 1 ixazomib 1 X-Rays 1 Videotape Recording 1 Valproic Acid 1 Trastuzumab 1 Sugars 1 Sorafenib 1 Platinum 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Lenalidomide 1 Lapatinib 1 LY 2275796 1 Injections, Subcutaneous 1 Fluorouracil 1 Everolimus 1 Curcumin 1 Crizotinib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Terminated

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡